Please note that eDoc will be permanently shut down in the first quarter of 2021!      Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Quick Search
My eDoc
Session History
Support Wiki
Direct access to
document ID:

          Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Publikationen des W. G. Kerckhoff-Instituts     Display Documents

ID: 474510.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Publikationen des W. G. Kerckhoff-Instituts
Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model
Authors:Kamlah, F.; Eul, B. G.; Li, S.; Lang, N.; Marsh, L. M.; Seeger, W.; Grimminger, F.; Rose, F.; Hanze, J.
Date of Publication (YYYY-MM-DD):2009
Title of Journal:Cancer Gene Ther
Issue / Number:3
Start Page:195
End Page:205
Audience:Not Specified
Abstract / Description:Different routes for the in vivo administration of synthetic siRNA complexes targeting lung tumors were compared, and siRNA complexes were administered for the inhibition of hypoxia-inducible factor (HIF-1alpha and HIF-2alpha). Intravenous jugular vein injection of siRNA proved to be the most effective means of targeting lung tumor tissue in the Lewis lung carcinoma (LLC1) model. In comparison, intraperitoneal injection of siRNA was not suitable for targeting of lung tumor and intratracheal administration of siRNA exclusively targeted macrophages. Inhibition of HIF-1alpha and HIF-2alpha by siRNA injected intravenously was validated by immunohistofluorescent analysis for glucose-transporter-1 (GLUT-1), a well-established HIF target protein. The GLUT-1 signal was strongly attenuated in the lung tumors of mice treated with siRNA-targeting HIF-1alpha and HIF-2alpha, compared with mice treated with control siRNA. Interestingly, injection of siRNA directed against HIF-1alpha and HIF-2alpha into LLC1 lung tumor-bearing mice resulted in prolonged survival. Immunohistological analysis of the lung tumors from mice treated with siRNA directed against HIF-1alpha and HIF-2alpha displayed reduced proliferation, angiogenesis and apoptosis, cellular responses, which are known to be affected by HIF. In conclusion, intravenous jugular vein injection of siRNA strongly targets the lung tumor and is effective in gene inhibition as demonstrated for HIF-1alpha and HIF-2alpha.
Free Keywords:Animals; Basic Helix-Loop-Helix Transcription Factors/*antagonists &; inhibitors/biosynthesis/genetics/physiology; Carcinoma, Lewis Lung/genetics/pathology/*therapy; Down-Regulation; Gene Therapy/*methods; Hypoxia-Inducible Factor 1, alpha Subunit/*antagonists &; inhibitors/biosynthesis/genetics/physiology; Imines/administration & dosage; Injections, Intraperitoneal; Injections, Intravenous; Jugular Veins; Lipids/administration & dosage; Lung Neoplasms/genetics/pathology/*therapy; Mice; Mice, Inbred C57BL; Neoplasm Proteins/*antagonists &; inhibitors/biosynthesis/genetics/physiology; Neovascularization, Pathologic/therapy; Polyethylenes/administration & dosage; *RNA Interference; RNA, Small Interfering/*administration &; dosage/genetics/pharmacokinetics/therapeutic use; Specific Pathogen-Free Organisms; Subcutaneous Tissue; Trachea
External Publication Status:published
Document Type:Article
Communicated by:N. N.
Affiliations:MPI für physiologische und klinische Forschung
External Affiliations:Department of Internal Medicine II/V, Justus Liebig University, Giessen, Germany.
Identifiers:ISSN:1476-5500 (Electronic) 0929-1903 (Linking)
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.